Ph II KUPENG trial of Vebreltinib in Advanced MetExon14 and NSCLC

Jarushka Naidoo shared a post on X about a recent paper by Jin-Ji Yang et al. published in Journal of Clinical Oncology.

“Vebreltinib for Advanced Non–Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study”

Authors: Jin-Ji Yang, Yan Zhang, Lin Wu, Pei-Long Zhang, Yi-Long Wu et al.

“Ph II KUPENG trial of Vebreltinib in Advanced MetExon14 and NSCLC in Journal of Clinical Oncology:

• 52pts
• ORR 75% (77.1% tx-naive), DCR 96.2%
• mDoR 15.9m, mPFS 14.1m, mOS 20.7m
• TRAEs: peripheric edema 82.7%, prolongation of QT 30.8%, elevation of creat 28.8%

Interesting, watch this space.”

Source: Jarushka Naidoo/X

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland.

She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.

She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.